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A B S T R A C T
Objective: This study analyzed whether HPV (human papillomavirus) testing contributes towards
deﬁning histological abnormalities in women with atypical glandular cells (AGC) diagnosed at cervical
cytology.
Study design: One hundred and eight women with conventional cervical cancer screening smears
suggestive of AGC not otherwise speciﬁed (AGC-NOS) and favor neoplastic (AGC-FN) were consecutively
enrolled. All women underwent colposcopic examinations and biopsy was performed according to the
cytopathologic and/or colposcopic abnormalities present. All specimens were tested for high risk HPV
genotypes by Roche’s polymerase chain reaction reverse line blot assay. The chi-square test was used to
evaluate the association between HPV ﬁndings and a diagnosis of high-grade pre-invasive or invasive
disease (CIN 2 or worse) taking negative tests or CIN 1 as a reference. Odds ratios (OR) with their
respective 95% conﬁdence intervals (95%CI) were used to evaluate the magnitude of the association
between HPV testing and CIN 2 or worse. Sensitivity, speciﬁcity and their respective 95% conﬁdence
intervals (95%CI), positive predictive values (PPV) and negative predictive values (NPV) were also
calculated.
Results: Final diagnosis revealed a negative outcome in 80 cases (74%), cervical epithelial neoplasia 1
(CIN 1) in 13 cases (12%), CIN 2 or worse in 12 cases (11%) and glandular neoplasia in 3 (3%) cases. The
overall detection rate of HPV was 21% (23/108). Neoplasia was signiﬁcantly associated with positive
HPV-DNA in women with AGC-NOS (OR = 15.21; 95%CI: 2.64–87.50); however, there was no signiﬁcant
association between a histological diagnosis of neoplasia and HPV positivity in women with AGC-FN
(OR = 3.00; 95%CI: 0.36–24.92). The sensitivity, speciﬁcity, positive predictive value and negative
predictive value of HPV-DNA testing for the detection of CIN 2 or worse in women with AGC-NOS were
71%, 86%, 29% and 97%, respectively. In women with AGC-FN, these values were 50%, 75%, 66% and 60%,
respectively.
Conclusions: HPV testing at the time of colposcopy for patients with AGC in whom no colposcopic
abnormality is found may be a powerful ancillary tool for identifying women at a high risk of underlying
signiﬁcant cervical lesions.
 2011 Elsevier Ireland Ltd. 
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Adenocarcinomas are the second most common type of
malignant cervical neoplasm. Squamous cell carcinomas represent
75–85% of all cases, while adenocarcinomas occur in 11–25% and
adenosquamous carcinomas in 2–3% of cases [1]. The natural* Corresponding author. Tel.: +55 19 35218008; fax: +55 19 32895935.
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Open access under the Elsevier OA license. history of the cervical adenocarcinoma is similar to that of the
squamous cell carcinoma, particularly in relation to the existence
of precursor lesions and their association with high-risk oncogenic
human papillomavirus (HPV) infection [2,3]. Adenocarcinoma in
situ (AIS) is known to be a precursor of invasive adenocarcinoma
and it is considered to be the glandular counterpart of cervical
intraepithelial neoplasia (CIN) 3. Similar HPV types have been
demonstrated in most invasive adenocarcinomas and AIS [4].
Lesions less severe than AIS are not as well characterized
epidemiologically or histologically [5,6]. Glandular lesions
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glandular intraepithelial lesions have shown a signiﬁcantly lower
rate of detection of HPV-DNA and it is suggested that the majority
of these diagnoses are unrelated to cervical carcinogenesis [4].
The Bethesda interpretation of atypical glandular cells deﬁnes
an increased level of risk, as opposed to a speciﬁc neoplastic
precursor entity. The changes made in the last revision (2001)
classiﬁed endocervical glandular cell abnormalities less severe
than AIS and invasive adenocarcinoma into two categories:
atypical glandular cells (AGC) not otherwise speciﬁed (NOS) and
AGC favor neoplastic (FN) because the risk of neoplasia associated
with the latter is substantially higher [7–9].
The low prevalence of AGC in cervical cytology, the relative
absence of ﬁndings at colposcopy and a broad spectrum of
differential diagnoses are factors that pose signiﬁcant diagnostic
challenges to cytopathologists and clinicians [1–4]. Cervical
neoplasia, principally of squamous origin, is the most frequent
neoplastic diagnosis in women referred for glandular endocervical
abnormalities, and the value of HPV testing in the clinical
management of women with this cytological diagnosis has
received attention in recent years [10–12].
High-risk HPV-DNA was detected by hybrid capture in 96% of
women with biopsy-conﬁrmed CIN 2 or CIN 3 and in 83% with
adenocarcinoma in situ or invasive cervical adenocarcinoma [10].
Using PCR, high-risk HPV was detected in 82%, 100% and 80%,
respectively, of biopsy-conﬁrmed cases of AIS, high-grade squa-
mous lesion and invasive adenocarcinoma [11]. The risk of cervical
neoplasia associated with infection by individual HPV types has
been examined to some extent. There are indications that the
detection of HPV 16 in women with glandular abnormalities in
cervical smears did not help differentiating squamous from
glandular lesions. However, the detection of HPV 18 can predict
glandular neoplasia as histologic diagnoses [12].
In fact, Castelsague et al. [2] conducted a multicenter study and
found a clear association between types 16 and 18 and cervical
adenocarcinoma, with odds ratios (OR) of 164.12 (95%CI: 76.09–
354.0) and 410.32 (95%CI: 167.44–1), respectively. Associations
were also found with types 59 and 33 (OR > 100) and with types
35, 45, 51 and 58 (OR > 18). Nonetheless, it is important to
emphasize the signiﬁcance of the diversity that exists within HPV
types, i.e., genomic differences with biological consequences
related to viral types 16 and 18. Asian-American and European
variants of HPV 16 are more prevalent in glandular and squamous
cell neoplasias, respectively. In fact, a study conducted in Brazil
showed that the Asian-American variant of HPV 16 was
signiﬁcantly associated with a histological diagnosis of glandular
neoplasia [13].
The 2006 consensus guidelines of American Society for
Colposcopy and Cervical Pathology (ASCCP) established that
neither the use of HPV-DNA testing alone nor a program of repeat
cervical cytology is acceptable as an initial screening test for all
subcategories of AGC and AIS, and included HPV-DNA testing
together with colposcopy and endometrial sampling in the initial
workup [14]. The 2002 version of the consensus guidelines
considered the data available for the assessment of the impact
of HPV-DNA testing on AGC to be limited and consequently made
no recommendations [15].
Recent epidemiological lines of evidence suggest that HPV-DNA
testing may yield good sensitivity and speciﬁcity for the detection
of signiﬁcant cervical lesions in women with atypical endocervical
glandular cells. There are some indications that endometrial
abnormalities tend to be found in women with AGC and a negative
HPV test, while squamous or glandular abnormalities of the cervix
are more common in those with a positive HPV test [16–18]. These
data suggest that HPV testing may help determine the area in
which the initial workup should be focused: in the cervix or in theendometrial/uterine canal. The present study was therefore
designed to examine the relationship between HPV-DNA testing
and pathological outcomes in women referred because of AGC-
NOS or AGC-FN at cervical cytology.
2. Materials and methods
2.1. Patient selection and clinical samples
The study’s protocol was approved by the Institution’s Internal
Review Board and all selected women voluntarily signed an
informed consent form prior to enrollment. One hundred and eight
women with conventional cervical cancer screening smears
suggestive of endocervical glandular abnormalities (AGC-NOS or
AGC-FN) were enrolled consecutively to this study. These women
were recruited at the colposcopy clinics of the State University of
Campinas, Brazil, between March 2002 and March 2005. AGC-NOS
was diagnosed in 92 women and AGC-FN in 18 women. Thirty-ﬁve
cases of AGC with high-grade squamous intraepithelial lesion
(HSIL) and 14 cases of AIS were previously excluded from the study
because of the well-established association of these types of
cytological diagnoses with HPV infection. All the cervical smears
were analyzed by the same cytopathologist in accordance with the
2001 Bethesda System (TBS) [4].
Following enrollment, all women were subjected to a
thorough pelvic examination, including the collection of
samples for a second cervical smear and polymerase chain
reaction (PCR) and genotyping, colposcopy and directed punch
biopsy in accordance with the cytopathologic and/or colposcopic
abnormalities present. Punch biopsy was taken when a
suspicious image was completely identiﬁed. Women with a
suspicious image penetrating in the cervical canal, or an
unsatisfactory colposcopy but with a second abnormal cervical
smear underwent cervical conization.
All women were also subjected to pelvic ultrasound examina-
tions, and whenever endometrial abnormalities were suspected,
uterine curettage was performed. Women with invasive cervical or
endometrial carcinoma were treated according to the clinical
guidelines. Samples for histology were obtained from punch, cone
biopsies or hysterectomy specimens and in cases in which the
woman had undergone more than one histological examination
the most severe diagnosis was the one considered.
Biopsies were performed in 81 of the 110 women initially
recruited for the study. In the remaining 29 cases, colposcopy was
negative, a second cervical smear was negative and both clinical
and ultrasonographic evaluations of the pelvis were normal;
therefore, the ﬁnal diagnosis was negative for neoplasia. Four-
monthly follow-up visits were scheduled for these 29 women.
Since all of them had negative cervical smears after two follow-up
visits, they were considered free of neoplasia and were included in
this study together with the other women whose histological
diagnosis was negative for neoplasia. b-globin, a reaction internal
control, could not be detected in two cases of women submitted to
biopsy resulting in a sample of 108 women for HPV-DNA testing.
2.2. HPV-DNA testing
HPV detection and typing were performed using Roche line blot
assays. This assay involved the hybridization of a 450-nucleotides
PCR amplicon generated by the PGMY primer set to a nylon strip
containing immobilized probes. The strip contained 2 levels of b-
globin control probes, 18 high-risk HPV (HR-HPV 16, 18, 26, 31, 33,
35, 39, 45, 51, 52, 55, 56, 58, 59, 68, 73, 82, and 83) probes and 9
low-risk HPV (LR-HPV probes 6, 11, 40, 42, 53, 54, 57, 66, and 84)
The primers PGMY09 and PGMY11 (14), adapted from primers
MY09 and MY11, detect genital HPV types at a higher rate than
Fig. 1. (A) Atypical glandular cells not otherwise speciﬁed (AGC-NOS), HPV positive. Histological follow-up showed CIN 3 (Pap stain, 400). (B) Atypical glandular cells not
otherwise speciﬁed (AGC-NOS), HPV negative. Histological follow-up showed CIN 3 (Pap stain, 400). (C) Atypical glandular cells favor neoplastic (AGC-FN), HPV positive.
Histological follow-up showed CIN 3. (Pap stain, 400). (D) Atypical glandular cells favor neoplastic (AGC-FN), HPV negative. Histological follow-up showed endometrial
adenocarcinoma (Pap stain, 400).
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HPV detection method utilized in many countries, but there are
indications that the Roche Linear Array is the assay is the most
sensitive, as it was able to reveal the HPV type present in the
specimens [21].
2.3. Histopathology
The specimens were reviewed according to the WHO criteria
[22] and classiﬁed as: CIN 1, CIN 2, CIN 3, invasive squamous
carcinoma, in situ adenocarcinoma, invasive cervical adenocarci-
noma, endometrial adenocarcinoma and synchronous gynecologi-
cal adenocarcinomas that included endocervical, endometrial,
tubal and ovarian origin (Fig. 1). ‘‘No Neoplastic Diagnosis’’
included cervicitis, squamous metaplasia, tubal metaplasia, tunnel
cluster hyperplasia, microglandular hyperplasia and polyps. All
histological analyses were carried out at the same laboratory of
pathology and diagnosed by the same pathologist, who was
unaware of the cytological diagnoses
2.4. Statistical analysis
The chi-square test was used to evaluate the association
between HPV ﬁndings and a diagnosis of high-grade pre-invasive
or invasive disease (CIN 2 or worse) taking negative tests or CIN 1
as a reference. Odds ratios (OR) with their respective 95%
conﬁdence intervals (95%CI) were used to evaluate the magnitude
of the association between HPV testing and CIN 2 or worse.
Sensitivity, speciﬁcity and their respective 95% conﬁdence inter-
vals (95%CI), positive predictive values (PPV) and negative
predictive values (NPV) were also calculated. The Mann–Whitney
test was used to evaluate the difference of woman’s age at ﬁnal
diagnosis.3. Results
Final diagnosis revealed a negative outcome in 80 cases (74%),
CIN 1 in 13 cases (12%), CIN 2 or worse in 12 cases (11%) and
glandular neoplasia in 3 cases (3%). The women with glandular
neoplasia are older than the women with the other ﬁnal diagnosis.
The women with glandular neoplasia were signiﬁcantly older
than those women with the other ﬁnal diagnosis and this
difference was statistically signiﬁcant. The overall HPV detection
rate was 21% (23/108) and all infections were by high risk HPV
types. HPV-DNA testing was positive in 9.6% and 15.3% of the
women whose results at follow-up consisted of an absence of
malignancy or CIN 1, respectively. Conversely, 9 women (75%) with
a result of CIN 2 or worse tested positive for HPV-DNA. All the cases
of glandular neoplasia detected were found in HPV-DNA-negative
women with AGC-FN (Table 1).
Women with AGC-NOS were detected with CIN 2 or worse in
7.6% (7/92) of the cases. Of these, 71% (5/7) were HPV-DNA-
positive. Of 75 HPV-DNA-negative cases, only two harbored CIN 2
or worse. There were no cases of endocervical or endometrial
adenocarcinomas, or adenocarcinomas at any other site, in the
women with AGC-NOS. Thirty-one percent (5/16) and 19% (3/16)
of women with AGC-FN were detected, respectively, with
squamous neoplasia (CIN 2 or worse) and invasive adenocarcino-
ma. HPV-DNA testing was positive in 50% of the women who had
clinically signiﬁcant lesions. Neoplasia was signiﬁcantly associated
with a positive HPV-DNA test in women with AGC-NOS
(OR = 15.21; 95%CI: 2.64–87.50). However, there was no signiﬁ-
cant association between the histological diagnosis of neoplasia
and HPV positivity in women with AGC-FN (OR = 3.00; 95%CI:
0.36–24.92) (Table 2).
The sensitivity, speciﬁcity, positive predictive value and
negative predictive value of HPV-DNA testing for the detection
Table 1
Final diagnosis in women with AGC.
Final diagnosis AGC-NOS AGC-FN Total HPV+/Total ﬁnal diagnosis Mean age
n (%) n (%) n (%) n (%)
Negative 73 (79) 7 (44) 80 (74) 12/80 (9.6) 42.8 (17–76)
CIN 1 12 (13) 1 (6) 13 (12) 2/13 (15.3) 37.3 (18–52)
CIN 2 or worse 7 (8) 5 (25) 12 (11) 9/12 (75.0) 42.1 (28–56)
Glandular neoplasia 0 3 (25) 3 (3) 0/3 (0) 66 (57–71)
Total 92 (100) 16 100) 108 (100) 23(100) 42.7 (17–74)
Negative or non neoplastic diagnosis, CIN – cervical intraepithelial neoplasia.
The Mann–Whitney TEST showed that the women with glandular neoplasia are older than those women with the other ﬁnal diagnosis.
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97%, respectively. In women with AGC-FN these values were 50%,
75%, 66% and 60%, respectively. The accuracy of HPV testing for the
detection of CIN 2 or worse was higher in women with AGC-NOS
compared to women with AGC-FN (Table 3).
3.1. Comments
The ﬁndings of the present study suggest that the probability of
detecting a signiﬁcant cervical lesion, either squamous or
glandular, in women with AGC-NOS and a negative HPV-DNA
test is low. On the other hand, HPV-DNA testing does not appear to
add any signiﬁcant clinical information in cases of women with
AGC-FN, since the likelihood of a glandular lesion, especially of
endometrial origin, is higher in these cases, and is not dependent
on the result of the HPV-DNA test. It should be considered that a
sample of 18 women referred for AGC-FN has a low statistical
power and, therefore, it is not possible to show statistically an
association, even if one exists. Irrespective of this fact, however, the
ﬁndings of the present study support the ASCCP recommendation
that indicate colposcopy with endocervical sampling for women
with all subcategories of AGC and suggest the high-risk HPV-DNA
testing as an additional guide to follow-up after initial colposcopic
evaluation and endocervical sampling and to help detect small or
difﬁcult-to-sample neoplastic cervical lesions [14].Table 2
Association of HPV positivity and severity of histopathological diagnosis.
Cytological diagnosis Final diagnosis
CIN 2 or worse Negative/CIN 1 OR (95%CI)
n (%) n (%)
AGC-NOS
Age (years)
45 2 (29) 34 (40) 0.6 (0.11–3.27)
44 5 (71) 51 (60)
Total 7 (100) 85 (100)
HPV status
HPV+ 5 (71) 12 (14) 15.21 (2.64–87.50)
HPV 2 (29)a 73 (86)
Total 7 (100) 85 (100)
AGC-FN
Age (years)
45 6 (75) 4 (50) 3.00 (0.36–24.92)
44 2 (25) 4 (50)
Total 8 (100) 8 (100)
HPV status
HPV+ 4 (50) 2 (33) 3.00 (0.36–24.92)
HPV 4 (50)b 6 (77)
Total 8 (100) 8 (100)
AGC-NOS – Atypical glandular cells not otherwise speciﬁed, AGC-FN – Atypical
glandular cells favor neoplastic.
a One case diagnosed as CIN 2 and one case diagnosed as CIN 3.
b Three cases of adenocarcinoma, two endometrial and one synchronous
gynecological adenocarcinomas that included endocervical, endometrial, tubal
and ovarian origin.In this study, the overall prevalence of HPV in women referred
for AGC was similar to that observed in other reports. The total
prevalence of HPV has been reported to range from 24.3% to 30.4%
in two large series [16,17]. In women with AGC of presumed
cervical origin, the prevalence of HPV was 20.2% in one report [18].
Considering the subclassiﬁcations of AGC diagnosis, the prevalence
of HPV in women with AGC-NOS and AGC-FN was, respectively,
18,4% and 37.%. Chen and Yang [18] detected prevalence of HPV of
17% in women with atypical endocervical cells not otherwise
speciﬁcation (AEC-NOS), but the HPV prevalence in women with
atypical endocervical cells favor neoplastic (AEC-FN) was higher
(86%) when compared with those observed in this study. This is
probably due to the fact that all cases of endometrial carcinoma,
obviously HPV negative had been diagnosed in women referred for
AGC-NOS in this study.
The accuracy of HPV testing in detecting CIN 2 or worse was
higher in women with AGC-NOS compared to that in women with
AGC-FN in this study. A literature search indicated that the HPV
testing had an overall 90% sensitivity, 79% speciﬁcity, 53% positive
predictive value and 97% negative predictive value [23]. Schantz
et al. [16] observed that the sensitivity of HPV testing in women
with AGC for HPV-associated disease was 81.3%. Chen and Yang
[18] reported similar rates of sensitivity, speciﬁcity, positive
predictive value and negative predictive value (respectively, 91.0%,
91.2%, 62.5% and 98.4%).
Several studies have demonstrated that the HPV positivity is
higher in women with signiﬁcant cervical lesions [7,9–12]. In fact,
Schnatz et al. [16] showed that the HPV-associated disease among
cases testing positive for HPV was 40% compared with 4% among
HPV-negative cases. In the present study, HPV-DNA testing was
positive in the majority of women with AGC-NOS and clinically
signiﬁcant lesions. However, 50% of the women with a clinically
signiﬁcant histological lesion who were referred for AGC-FN were
found to be HPV-DNA-negative. Chen and Yang [18] detected HPV
positivity in 55.8% of women with AEC-NOS and with signiﬁcant
cervical lesions. The frequency of HPV positivity in women referred
with AEC-FN and with signiﬁcant cervical lesions was 91.7%.
It has been established that neither HPV-DNA testing nor repeat
cervical cytology is sensitive enough to be used alone as an initial
screening test for women with AGC. HPV testing has limitations
even considering its high sensitivity for the detection of cervical
lesions [10,12,18]. In fact, in this study, 2.6% of the women with
AGC-NOS and a negative HPV-DNA test harbored a clinically
signiﬁcant lesion (CIN 2 or CIN 3). Of 251 women with AEC and a
negative HPV test, Chen and Yang [18] found one case (0.4%) of CIN
2 and 3 cases (1.2%) of adenocarcinoma in situ. HPV-DNA testing
also can obviously miss non-HPV associated neoplasia arising in
the endometrium or the fallopian tube. In this study, two
endometrial and one multiple HPV-DNA-negative adenocarcino-
mas were detected in women with AGC-FN. On the other hand,
Chen and Yang [18] detected a signiﬁcant number of endometrial
abnormalities in women referred for AEC-NOS. In fact, correctly
classifying the cell origin on cervical cytology specimens is
challenging for most practicing cytopathologists. These ﬁndings
Table 3
Sensitivity, speciﬁcity, positive and negative predictive values of HPV testing in women referred with AGC for the clinical detection of signiﬁcant lesions (CIN 2 or worse).
AGC-NOS AGC-FN
Percentage 95%CI Percentage 95%CI
Sensitivity 71% 38–105% 50% 15–85%
Speciﬁcity 86% 78–93% 75% 78–93%
Positive predictive values 29% 66%
Negative predictive values 97% 60%
Accuracy 85% 63%
AGC-NOS – Atypical glandular cells not otherwise speciﬁed, AGC-FN – Atypical glandular cells favor neoplastic, 95%CI – 95% Conﬁdence interval.
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evaluation in women aged 35 years and in women referred
because of endocervical AGC-NOS or -FN.
Age is a key factor in determining the frequency and type of
neoplasia found in women with AGC. There is a higher risk of CIN 2,
3 and AIS in premenopausal women compared to postmenopausal
women, premenopausal women with AGC having a lower risk of
endometrial hyperplasia or cancer [18–22]. In this context, age and
clinical presentation rather than an HPV-DNA test result should
dictate appropriate management (i.e., endometrial sampling) in
older women, since this is the age-group at greater risk for
endometrial and metastatic neoplasms [7,18]. In fact, in the
present study, all the cases of adenocarcinoma were detected in
women over 50 years of age, and in all cases these women were
HPV-DNA-negative. These data are in agreement with other
studies that showed that the HPV-negative lesions are more
common in women aged >50 years [16,24].
This study showed that 79% (73/92) of the women with a
cytological diagnosis of AGC-NOS could theoretically have been
managed conservatively based on their negative HPV-DNA test.
Several other studies have also indicated that the HPV testing may
be useful in women with AGC [16–18,24,25]. Chen and Yang [18]
reported that up to 80% of women with a cytological diagnosis of
atypical endocervical cells (AEC) could be managed conservatively
with either cytological follow-up or further HPV testing. Saqi et al.
[25] suggested that HPV-DNA testing may constitute a reliable
alternative to colposcopy and endocervical sampling for the
management of initial diagnoses of AGC. Considering that not
all patients with AGC have signiﬁcant pathological lesions and that
glandular lesions are subtle and often located high in the
endocervical canal, these authors believe that such lesions may
remain undetected, resulting in false-negative reports at initial
colposcopic examinations. Therefore, physicians could conﬁdently
manage women with positive HPV tests aggressively with
colposcopy and endocervical sampling, while HPV-negative
patients could be monitored conservatively with repeat cytology.
The present results suggest that HPV-DNA testing at the time of
colposcopy in patients with AGC and normal colposcopy may
constitute a powerful tool for identifying women at risk of
signiﬁcant cervical lesions high in the cervical canal. HPV-DNA
testing in these situations may reduce the number of unnecessary
colposcopies and endocervical curettages in women with asymp-
tomatic benign cervical abnormalities. However, attention should
always be paid to potential lesions of a glandular nature.
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